EGF and breast cancer: Using this approach, we identified three differentially enriched pathways with prognostic value in EA patients with higher enrichment of EGF signaling (p = 0.02, optimal enrichment cutoff = 0.334) and estrogen-dependent breast cancer signaling (p = 0.076, optimal enrichment cutoff = 0.268) being associated with worse prognosis, while a better survival was observed for enrichment of DNA repair (p = 0.03, optimal enrichment cutoff = 0.304).